Wilex subsidiaries
ENGLISH DEUTSCH
WILEX AG has enhanced its core product development business with complementary activities. For an integrated approach to oncology in diagnostics and therapeutics, WILEX added in vitro diagnostic tests to its product portfolio and expanded its R&D activities to include an innovative technology platform for antibody drug conjugates and customer specific research.
Heidelberg Pharma GmbH
Heidelberg Pharma AG was acquired in March 2011 following WILEX’s shareholders approval of the acquisition at an extraordinary general meeting. The company became a wholly owned subsidiary of WILEX AG and is based in Ladenburg near Heidelberg. Since the conversion of the companies corporate form on 1 December 2011 the company operates under the name Heidelberg Pharma GmbH.
The company has 40 employees and is managed by Dr Jan Schmidt-Brandt (CEO). Heidelberg Pharma offers customer specific contract services in two fields. First, an innovative conjugate platform technology for therapeutic antibodies (antibody drug conjugates, ADCs) is being utilised in the further development of antibodies. This ADC technology has the potential to improve the efficacy of many antibody-based therapies, including those currently on the market. Primarily, Heidelberg Pharma intends to license this technology to other partners on a per-customer basis as a means of generating revenue. Second, Heidelberg Pharma also operates a service unit for preclinical work on drug metabolism, pharmacology and pharmacokinetics in oncology and infl ammatory diseases.
WILEX Inc.
WILEX Inc. was founded in October 2010 as a wholly owned US subsidiary of WILEX AG in order to acquire the assets of Oncogene Science, a former commercial business unit of Siemens Healthcare Diagnostics Inc. WILEX Inc. is headquartered in Cambridge, Massachusetts USA, and has ISO certifications for the manufacture of biomarker tests.. The company is managed by Professor Olaf G. Wilhelm (CEO) Peter Llewellyn-Davies (CFO) as well as a team of dedicated professionals from the former Oncogene Science operations.
WILEX Inc. employs eleven staff and specialises in manufacturing and sales of in vitro diagnostics and biomarker tests in oncology. In the field of in vitro diagnostics, a distinction is made between ELISA tests for measuring proteins in the blood and immunohistochemical (IHC) tests which are performed on tissue. These assays are marketed under the Oncogene Science brand to existing and new customers in the pharmaceutical and reference laboratory industries.
